Valeant Pharmaceuticals International (VRX)
Valeant Pharmaceuticals International Revenues: 856.10M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VRX Revenues Rankings
| Overall | 81st percentile | 816 of 4431 |
| Sector | 87th percentile | 57 of 471 in Healthcare |
| Industry | 81st percentile | 2 of 11 in Drug Delivery & Accessories |
VRX Revenues Range, Past 5 Years
| Minimum | 173.32M | Mar 2009 |
| Maximum | 856.10M | Mar 2012 |
| Average | 333.71M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these VRX related companies
VRX News
Jeffrey Ubben's ValueAct Capital has bought around 1.5m shares of $VRX over past month (via various SEC Form 4's). Owns 17.1m shares now
about 2 days ago by marketfolly
about 2 days ago by marketfolly
$VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 33 Revised 5/24/2012 http://stks.co/3yvG #corpgov
about 8 days ago by corpgovnet
about 8 days ago by corpgovnet
$VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 33 Revised 5/24/2012 New Information #corpgov
about 8 days ago by corpgovnet
about 8 days ago by corpgovnet
Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal for C$28M
May 24, 7:58AM Benzinga
May 24, 7:58AM Benzinga
$VRX Valeant Pharmaceuticals International (VRX): How I Voted – Proxy Score 50 http://stks.co/3xWY #corpgov #VRX #Valeant
about 9 days ago by corpgovnet
about 9 days ago by corpgovnet
Yet Another Solid Momentum Value Stock Portfolio Beating S&P 500 Handily http://stks.co/3v8r $MA $ORLY $TJX $AAP $VRX
about 11 days ago by tailwind
about 11 days ago by tailwind
Momentum on value stocks: beating S&P by big margin http://stks.co/3t6S $ORLY $GOOG $MA $VRX $TJX $AAP
about 14 days ago by tailwind
about 14 days ago by tailwind
Boxer Shorts include $FSLR and $VRX. Look for the next move in VRX to be down around 46. Video at http://stks.co/3rGp
about 16 days ago by thetechtrader
about 16 days ago by thetechtrader
Top 4 Stocks In The Drug Delivery Industry With The Highest Operating Margin
May 07, 2:10AM Benzinga
May 07, 2:10AM Benzinga
$VRX http://stks.co/3geT An engulfing bearish reversal bar Thursday on heavy volume - look to short on any bounce
about 27 days ago by TraderFlorida
about 27 days ago by TraderFlorida
$VRX big engulfing day a couple sessions ago. Huge volume. Looks ready to go lower http://stks.co/3gcq
about 27 days ago by financialtrader
about 27 days ago by financialtrader
$VRX Exactly why I never buy pharma stocks. This kind of crap happens so often it's prophetic.
about 29 days ago by IncrementalWealth
about 29 days ago by IncrementalWealth
News related to $VRX, currently -9.9% since open: 'Valeant posts 1Q loss on dermatology deal costs' http://stks.co/3eWN
about 29 days ago by TradeBot
about 29 days ago by TradeBot
$VRX getting killed after earnings release, breaking down below 50 day MA. I never found their EPS release schedule.
about 29 days ago by Global_Trader
about 29 days ago by Global_Trader
Valeant Pharmaceuticals (VRX) Posts Q1 EPS of 99c; Boosts FY12 Outlook
May 03, 8:10AM Street Insider
May 03, 8:10AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VRX | 48.66 | +0.74 | +1.54% | 14.92B |
| VRTX | 60.04 | -0.14 | -0.23% | 12.63B |
| VRTS | 70.88 | +0.51 | +0.72% | 545.78M |
| VRTB | 1.260 | -0.00 | -0.01% | 16.56M |
| VRTA | 1.10 | -0.04 | -3.51% | 6.974M |
| VRSN | 38.23 | -0.39 | -1.01% | 6.098B |
| VRSK | 47.90 | +0.01 | +0.02% | 7.893B |
| VRS | 1.15 | +0.04 | +3.60% | 60.48M |
| VRNT | 28.72 | -0.32 | -1.10% | 1.116B |
| VRNM | 3.58 | +0.16 | +4.68% | 45.14M |
